BURLINGTON, Mass., Dec. 3, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the U.S. market for predictive personalized drugs is forecasted to double, increasing from $9.2 billion in 2013 to $18.2 billion in 2019. The rapid growth reflects a strong pipeline of promising personalized medicines.

The new Strategic Insights report entitled, What You Need to Know to Create or Sustain a Personalized Medicine Strategy for Your Company, also finds that oncology therapies will continue to dominate the predictive personalized medicine market, capturing 88 percent of U.S. sales in 2019. In addition, predictive personalized drugs to treat cancer indications are forecast to account for more than a third of total U.S. oncology sales in 2019.

"There's booming interest in personalized medicine and the development of pharmaceutical products that depend on the results of a pretreatment diagnostic or assay to determine use, most notably in oncology treatment," said Decision Resources Group Senior Vice President Kate Hohenberg. "While lucrative, companies invested in advancing predictive personalized medicine face a wide range of challenges including regulatory, reimbursement and clinical development hurdles, among others."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


For more information, contact:

Decision Resources Group
Christopher Comfort

SOURCE Decision Resources

Pharma Should Factor Medication Adherence Into Drug Development

View Now